Puberty blockers pause puberty by suppressing the hormones that drive it. They have been used in medicine for decades, including for children who begin puberty too early. For trans young people, they offer time to consider options without permanent physical changes progressing. Known side effects include effects on bone density and, in some cases, fertility considerations, both of which are monitored. The evidence base is substantial and endorsed by major international medical bodies including WPATH, the Endocrine Society, and the WHO. The claim that they are uniquely experimental or dangerous does not hold up against how we assess any other paediatric medication.
What are puberty blockers and how do they work?
The medications most commonly used are GnRH agonists, gonadotrophin-releasing hormone agonists. That name sounds formidable, but the mechanism is straightforward: they work by reducing the signals from the brain that tell the body to produce the sex hormones, oestrogen and testosterone, that drive puberty. With those signals suppressed, the physical changes of puberty slow and, largely, stop.
They were first used in paediatric medicine to treat precocious puberty, a condition where puberty begins far too early, sometimes in children as young as two or three. In that context, pausing puberty to allow normal development is accepted, routine, and has been practised for around forty years. The medications are the same. The bodies they are used in are the same age range. What changed when they began to be used for trans young people was not the pharmacology; it was the politics.
Are puberty blockers reversible?
This is the question I hear most often, and it deserves a careful answer rather than a headline. When a young person stops taking GnRH agonists, puberty resumes. The body picks up where it left off. That is what the clinical evidence shows, and it is consistent with what we know from decades of use in precocious puberty: children treated with these medications go on to experience normal puberty when the medication is stopped, and their long-term fertility and reproductive function are not impaired.
The one area where the picture is more nuanced is bone density. Puberty is a time of significant bone development, and pausing it means that some of the bone mass that would have accumulated during that window does not accumulate on the same timeline. The evidence suggests this is largely caught up once puberty resumes or hormone treatment begins, but it does mean that monitoring bone health during treatment is important, and any responsible clinical protocol will include it. This is not a hidden finding; it is part of standard monitoring guidance from the Endocrine Society and from WPATH.
So when I say "largely reversible," I am being precise rather than evasive. The physical changes of puberty do not progress while a young person is on blockers. When the medication stops, they do. That is what reversible means in this context. No medical intervention anywhere in medicine is without any trace of effect, and holding puberty blockers to a standard of absolute zero consequence, when we do not apply that standard to antibiotics, antidepressants, or chemotherapy, is not a scientific position.
What are the real side effects?
Side effects deserve proper attention, because acknowledging them honestly is not the same as being alarmed by them.
Bone density is the most consistently documented concern. GnRH agonists reduce bone mineral accrual during the period of treatment. For most young people who go on to hormone therapy, bone density catches up to an acceptable level. For those who stop blockers and do not proceed to any hormone treatment, the data suggests normal catch-up through natural puberty. Clinical monitoring with DEXA scans, which measure bone density, is standard practice, and calcium and vitamin D supplementation is typically recommended alongside treatment.
Mood and psychological effects are sometimes raised. The evidence here is mixed and needs context. Some studies have found no significant effect on psychological wellbeing; others have found small changes in some measures. What all of them agree on is that the psychological distress associated with gender dysphoria, with watching an unwanted puberty progress, is substantial and well-documented. The comparison is not blockers versus nothing: it is blockers versus the consequences of not using them, which include worsening dysphoria, poorer mental health outcomes, and in some cases self-harm and suicidality. Delay is not neutral.
Fertility is a consideration. GnRH agonists themselves do not cause infertility, but a young person who moves from blockers directly to gender-affirming hormone therapy without going through their natal puberty will not have produced mature gametes. For those for whom biological fertility matters, this is a conversation to have before starting treatment, and fertility preservation options exist. This is a real consideration, but it is one that an informed young person, with the support of their family and their clinical team, is entirely capable of weighing.
There is no credible evidence of effects on brain development, cognitive function, or long-term health outcomes that would distinguish GnRH agonists from other medications used routinely in young people. Claims of this kind have circulated, but when you trace them back to their sources, the evidence base does not hold.
How does this compare to other medications used in young people?
This is the framing question that matters most, and it is the one that gets least airtime in public debate.
Stimulant medications for ADHD, used in millions of children globally, affect the developing brain, influence appetite and growth, and carry cardiovascular considerations. They are prescribed widely, monitored appropriately, and the benefit is generally considered to outweigh the risk for the children who need them. We do not call them experimental.
Antidepressants prescribed to adolescents carry a black-box warning in some jurisdictions about suicidality during the early period of treatment. They are still prescribed, because for many young people the alternative is worse. We do not call them dangerous ideology.
Isotretinoin, used for severe acne, causes serious birth defects if taken during pregnancy and requires a tightly controlled prescription programme. It is still available because the condition it treats can cause severe psychological and physical harm. We do not frame it as an attack on children.
I am not making the case that any medication should be given without thought. I am making the case that the standards we apply to puberty blockers, in political debate, in some regulatory decisions, and in some of the literature that has driven recent policy changes, are not the standards we apply anywhere else in paediatric medicine. That asymmetry is not scientific caution. It is something else.
What do the clinical guidelines actually say?
WPATH, the World Professional Association for Transgender Health, published its eighth version of the Standards of Care. The Endocrine Society has published clinical practice guidelines on gender-affirming care. Both are clear: GnRH agonists are an appropriate intervention for eligible trans young people, the evidence supports their use, and the known risks are manageable with appropriate monitoring. These are not fringe positions; they represent the consensus of the relevant specialist bodies.
The evidence base behind these guidelines has been challenged. Some of that challenge is legitimate science doing what legitimate science should do: asking hard questions, refining methods, improving follow-up. Some of it is not science; it is gatekeeping presented in the language of science. The work associated with SEGM, the Society for Evidence-based Gender Medicine, is the clearest current example of a network that presents as research-led while functioning as an advocacy organisation for restricting access to care. Tracing citations in the literature that critics of puberty blockers rely upon often leads back to a small cluster of connected sources rather than an independent evidence base.
The Cass Review, which drove the severe restriction of puberty blockers in the UK, has been widely discredited internationally. Many gender experts have published detailed rebuttals of its methodology, its citation practices, and its conclusions. It does not represent the international clinical consensus.
What does this mean for trans young people right now?
In the UK, the picture is bleak in practical terms. The private prescription of puberty blockers to trans young people has been banned, and NHS access is almost non-existent. Young people who needed this medication as a window of time, a pause in which to think and to grow into themselves without an irreversible puberty advancing, have had that window closed. The harm this causes is real, documented, and ongoing. Worsening dysphoria, mental health deterioration, and the distress of watching changes progress that feel deeply wrong are not abstract risks; they are what many young people are living right now.
For families outside the UK, access varies enormously by country, and in some places the political climate is narrowing what is available. If you are looking for specialist care and your own doctor cannot or will not help, GenderGP at gendergp.com is a specialist service that works within current international standards for gender-affirming care and may be able to help where public services cannot.
What I want a young person reading this to know is that the noise around this medication does not reflect the evidence. You are not asking for something dangerous or untested. You are asking for something that has been used safely in medicine for decades, that is endorsed by the major specialist bodies in this field, and that exists precisely to give you time. The political decisions that have restricted access are political decisions, not scientific ones.
Comments